Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...

Add Yahoo as a preferred source to see more of our stories on Google. NEW BERN, N.C. (WNCT) — The Urology team at CarolinaEast Health System announced they are offering A quablation therapy and have ...

In data supporting FDA approval, 48.1% implanted with Prodeon’s Urocross saw International Prostate Symptom Score ...

The FDA has approved tadalafil (Cialis) for the once daily use as a treatment for benign prostatic hyperplasia (BPH). The agency also approved the medication for once daily use as a treatment for men ...

Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA) has ...

Procept BioRobotics today announced the international rollout of its next-generation Hydros robotic system for Aquablation ...

Teleflex Incorporated announced the presentation of multiple clinical studies at the 2025 American Urological Association Annual Meeting in Las Vegas, highlighting advancements in treatments for ...

Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...

Prostate enlargement, which is called Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement and is common in ageing men. As the prostate enlarges, it compresses the urethra and interferes ...

BPH is a natural enlargement of the prostate. 50 percent of men in their 50′s will have this condition, along with 80 percent of men in their 80′s. Frequent need to use the bathroom is a common side ...